Clinical Trials on Toxic Maculopathy in Hong Kong

Total 4 results

The University of Hong Kong

Completed

HIFU Ablation vs Fixed-dose RAI-131 Therapy in Moderate-sized Non-toxic MNG

Non Toxic Multinodular Goiter | High Intensity Focused Ultrasound | RAI

Hong Kong
Novartis

Completed

Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV)

Polypoidal Choroidal Vasculopathy

Hong Kong, Taiwan, Singapore, Korea, Republic of, Thailand
Mateon Therapeutics

Completed

Study Evaluating the Safety and Response of Fosbretabulin in Asian Patients With Polypoidal Choroidal Vasculopathy (PCV)

Polypoidal Choroidal Vasculopathy

United States, Hong Kong, Korea, Republic of, Singapore, Taiwan
Novartis Pharmaceuticals

Completed

Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT) (EVEREST II)

Age-related Macular Degeneration | Polypoidal Choroidal Vasculopathy

Japan, Taiwan, Hong Kong, Singapore, Thailand, Korea, Republic of, Malaysia

3

Subscribe